There are currently 44 ongoing clinical trials involving Progressive Supranuclear Palsy
Of the 44 trials,17 trials are in Phase III
Furthermore, 13 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Progressive Supranuclear Palsy, a central nervous system disorder. The largest number of ongoing clinical trials for Progressive Supranuclear Palsy is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Progressive Supranuclear Palsy-related drug trials.
AlzProtect SAS: The leading ongoing Progressive Supranuclear Palsy related clinical trial sponsor
AlzProtect SAS is the top sponsor for Progressive Supranuclear Palsy-related ongoing clinical trials.
Cambridge University Hospitals NHS Foundation Trust, Inha University Hospital, California Pacific Medical Center Research Institute, and Novartis AG are among other notable clinical trial sponsors involved in Progressive Supranuclear Palsy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer